Thread by @sakir_saiyed_

#Syngene 🧬 Way Forward:

The year ahead offers positive prospects reflecting the strong fundamentals of the global biopharmaceutical industry against a backdrop of potential further disruption due to the second wave of the pandemic.

https://twitter.com/sakir_saiyed_/status/1408757890156883974

1. The extension of our strategic collaboration with Bristol Myers Squibb until 2030 will provide scope for new areas of R&D within that relationship.

2. We have initiated multiple expansion and capability-building initiatives. The phase-III expansion of the Hyderabad laboratory is ongoing and will offer capacity for an additional 300 scientists.

3. We are collaborating with the Biotechnology Industry Research Assistance Council (BIRAC), under the National Biopharma Mission, to build a viral vector development and manufacturing plant for cell and gene therapy.

4. We have added capacity to our mammalian cell biologics manufacturing capabilities as well as commissioned a new microbial facility, further enhancing our services in biologics.

5. The Mangalore API plant has completed the qualification stage and beyond the GMP approval from the Indian regulator, we are working towards other regulatory approvals while adding clients and projects.

6. In conclusion, I am confident that our efforts will ensure long-term profitable growth that will create value for all stakeholders. - CFO, Sibaji Biswas, #Syngene